drugset / Trial / NCT06830395
Study of CM313 in Subject With IgA Nephropathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK) characteristics, Pharmacokinetics(PD) effects, and immunogenicity.
Timeline
- Start
- 2025-09
- Primary completion
- 2027-03
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUMROTATUG | Monoclonal antibody | — | Subcutaneous |